CClinicalTrials.gg
RecruitingNCT04020536Updated May 14, 2020

Real World Study of Classic Infectious Disease

An observational study in Brucelloses, Epidemic Hemorrhagic Fever and Kala-Azar, sponsored by Huashan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-05-14.

Sponsored by Huashan Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study aimed to collect and analyze clinical specimens of patients with classic infectious diseases in the real world. To investigate the epidemiological distribution of classic infectious diseases (brucellosis, epidemic hemorrhagic fever, kala-azar) and treatment options suitable for China.

Read the detailed description

Brucellosis is present in humans and animals in nearly 170 countries and regions around the world. In the 1950s and 1960s, brucellosis was seriously prevalent in China. In the 1970s, the epidemic gradually declined. It was basically controlled in the 1980s and early 1990s, but since the mid-1990s, the epidemic has continued to rise rapidly, and brucellosis It has become one of the fastest infectious diseases reporting the rising incidence rate. In 2016, 47,139 cases were reported, with an incidence rate of 3.44/100,000. The provinces with the most reported cases are Xinjiang Uygur Autonomous Region, Inner Mongolia Autonomous Region, Shanxi Province and Heilongjiang Province. However, in the southern non-pastoral areas of Guangdong Province and Guangxi Province, brucellosis outbreaks have occurred in recent years, and the incidence rates in Henan and Fujian provinces have continued to rise.

Hemorrhagic fever with renal syndrome, also known as epidemic hemorrhagic fever, is an infectious disease caused by the Hantavirus. The main clinical features are fever, exudation, hemorrhage, hypotensive shock, and kidney damage. It was once epidemic viral infection in China after viral hepatitis. In the 1980s, the number of cases reported exceeded 100,000. More than 1650,000 patients have been reported in China since 1950, including more than 47,000 deaths, with a total case fatality rate of approximately 2.89%. The number of people in the province accounted for more than 80% of the total number of people in the country. From 2004 to 2015, Shaanxi Province and the three northeastern provinces were the hardest hit areas of national hemorrhagic fever.

There are reports of sporadic leishmaniasis in China, but they are rare and lack corresponding epidemiological data. In 2015, 507 new cases of visceral leishmaniasis were reported, which was a high level in the past 10 years. However, the incidence rate remains at a low level of 0.0372/100,000. In recent years, visceral leishmaniasis is mainly distributed in the northwestern part of China, and there are many cases reported in the southwestern part of the country. The three areas with the highest incidence rate are Xinjiang Uygur Autonomous Region, Gansu Province and Sichuan Province. The cases in non-endemic areas are mainly adults who go to work in popular areas, and mainly male physical workers, while the popular areas are mainly infants and young children.

02

Conditions studied

  • Brucelloses
  • Epidemic Hemorrhagic Fever
  • Kala-Azar

Keywords

  • real world study
03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

This research plans to enroll 10000 outpatients or hospitalized patients (≥ 18 years old with the main diagnosis as classic infectious disease).Hospital selection follows a multi-stage sampling strategy.

Inclusion criteria

Brucellosis: Patients with any of the following confirmed the evidence.

  1. sample culture: Brucella;
  2. Specific antigen or antibody (IgG or IgM) positive. epidemic hemorrhagic fever:

1 specific antibody positive 2 Hantavirus RNA positive kala-azar:

  1. latent infection: rK39 antibody positive
  2. patients with the following evidence of kala-azar diagnosis: 1) bone marrow, spleen puncture sample culture: Leishmania; 2) bone marrow, spleen puncture sample smear: Leishmania; 3) clinical symptoms, history of exposure or epidemiology, and positive screening test (rK39 positive)

Exclusion criteria

Exclusion Criteria:

  1. Patient history data is incomplete
  2. HIV antibody positive and AIDS patients
  3. Patients who participated in other clinical trials during the same period.
  4. Pregnant, lactating women or women of childbearing age who are ready to conceive.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • kala-azar group

    Drug: Antibiotics

  • epidemic hemorrhagic fever group

    Drug: Antibiotics

  • brucellosis group

    Drug: Antibiotics

Interventions

  • DrugAntibiotics

    Local doctors prescribe available antibiotics to the patients according to the guideline and patients' condition

05

What researchers measure

Primary outcomes

  1. Number of patients With Prevalence Rate of specific infectious diseases(brucellosis, epidemic hemorrhagic fever, and kala-azar)

    Time frame: 1 day

Secondary outcomes

  1. Number of Participants With Successful Treatment of specific antibiotic therapy.

    Time frame: 30 days

  2. Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0

    Time frame: 2 years

06

Study locations

1 of 1 sites recruiting
  • Huashan Hospital of Fudan University
    Shanghai, Shanghai 200040, China
    • Wenhong Zhang, PhD,MD · Contact · zhangwenhong@fudan.edu.cn · +86 21 52889999
    • JIngwen Ai · Sub investigator
    • Yiqi Yu · Sub investigator
    • Haocheng Zhang · Sub investigator
    • Qiran Zhang · Sub investigator
    • Hanyue Zhang · Sub investigator
    Recruiting
07

Registry details

Key details

Study ID
NCT04020536
Lead sponsor
Huashan Hospital
Collaborators
First Affiliated Hospital of Xinjiang Medical University, First Affiliated Hospital of Harbin Medical University, The ninth Hospital of NanChang city, Luoyang Central Hospital, Second Affiliated Hospital of Nanchang University, The Fifth Affiliated Hospital Xinjiang Medical University, LanZhou University, Huzhou Central Hospital, First Affiliated Hospital of Fujian Medical University, Fuzhou Municipal Infectious Diseases Hospital, Henan Provincial People's Hospital, The First Affiliated Hospital of Lanzhou Medical University, Linyi People's Hospital, Nantong University, Nanyang Central Hospital, Qilu Hospital of Shandong University, Qianfoshan Hospital, Infectious Hospital of Jining City, The Affiliated Hospital of Jining Medical University and Zaozhuang City, The First Affiliated Hospital of Shanxi Medical University, First Affiliated Hospital Xi'an Jiaotong University, People's Hospital of Xinjiang Uygur Autonomous Region, Yuncheng Central Hospital, Zibo Central Hospital, The Second Affiliated Hospital of Henan Medical University, West Hospital of the First Affiliated Hospital of Guangxi University, The First Hospital of Jilin University, The Affiliated Hospital of Xuzhou Medical University, The First Affiliated Hospital with Nanjing Medical University, The First Affiliated Hospital of Anhui Medical University, The Second Hospital of Shandong University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Responsible party
Wen-hong Zhang (Chief of dpartment of infectious disease, Huashan Hospital) — Principal investigator
First posted
Jul 16, 2019
Start date
May 13, 2020 (estimated)
Primary completion
Jun 1, 2024 (estimated)
Completion
Jun 1, 2029 (estimated)
Last update
May 14, 2020

Study contacts

JingWen Ai, Doctor
Contact
jingwenai1990@126.com
+86 13764990804
YiQi Yu
Contact
yyq19890619@126.com
+86 13601637563

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion